All IndicationsPhase 3Phase 2Phase 2Phase 2Phase 2
Amyotrophic Lateral Sclerosis
4
Companies
5
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
IONS
Ionis Pharmaceuticals, Inc.
ION363
NRSN
NeuroSense Therapeutics Ltd.
Fixed dose combination Ciprofloxacin/Celecoxib
TEVJF
TEVA PHARMACEUTICAL INDUSTRIES LTD
40 mg glatiramer acetate
NRSN
NeuroSense Therapeutics Ltd.
Placebo
TEVA
Teva Pharmaceutical Industries Limited
40 mg glatiramer acetate
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals, Inc. | ION363 | Phase 3 | — | — | — |
| NRSN NeuroSense Therapeutics Ltd. | Fixed dose combination Ciprofloxacin/Celecoxib | Phase 2 | — | — | — |
| TEVJF TEVA PHARMACEUTICAL INDUSTRIES LTD | 40 mg glatiramer acetate | Phase 2 | — | — | — |
| NRSN NeuroSense Therapeutics Ltd. | Placebo | Phase 2 | — | — | — |
| TEVA Teva Pharmaceutical Industries Limited | 40 mg glatiramer acetate | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
1
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.